Tesofensine

Tesofensine (NS2330)

Small molecule Amino Acids · MW: 426.52 g/mol

Ask AI About This

Amino Acids

Small molecule

Molecular Weight

426.52 g/mol

Half-life

~200-300 hours

Research Score

76.0

Studies

Storage

Room temperature, protect from light

What is Tesofensine?

Tesofensine is a triple monoamine reuptake inhibitor originally developed for neurological diseases, discovered to cause dramatic weight loss — averaging 12.8 kg in 6 months at therapeutic doses.

Key Benefits & Mechanisms

Potent appetite suppression, increased metabolic rate, enhanced thermogenesis, improved mood during dieting, reduces food reward-seeking behavior

Research Summary

Phase II trials showed 12.8 kg average weight loss at 1.0 mg dose over 6 months. Simultaneously inhibits reuptake of norepinephrine, dopamine, and serotonin, producing appetite suppression and increased thermogenesis.

Related Peptides

AOD-9604

Anti-Obesity Drug (Modified GH Fragment)

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.

Metabolic

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA-c

MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis and exercise physiology. It activates AMPK, improves insulin sensitivity, and mimics the metabolic effects of exercise. Discovered at USC, it represents a new class of mitochondrial signaling peptides.

Metabolic

Oxyntomodulin

Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide

Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.

Weight Management

Cotadutide

MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist

Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.

Weight Management